Varda is building spacecraft-based manufacturing for pharmaceuticals using a bioreactor with a controllable gravity environment. Their in‑orbit prototype—flight‑tested after air‑drop and thermal cycling—produced a retinovir polymorph in ~1 day; the capsule will deorbit and be recovered in Utah after Mach‑25 reentry. The company targets recurring commercial demand to justify reusable launch cadence and orbital factories.